Search Within

Komal Lachhman Jhaveri

Formats
  1. Meeting Abstract (120)
  2. Journal Article (86)
  3. Review (5)
  4. Editorial (2)
  5. Correspondence (1)
  6. Guidelines (1)
Groups
  1. Breast Medicine Service (215)
  2. Department of Medicine (215)
  3. Solid Tumor Oncology Division (215)
  4. GSK Faculty (58)
  5. Survivorship Research (45)
  6. Epidemiology and Biostatistics (44)

More Groups

People
  1. Shanu Modi (35)
  2. Sarat Chandarlapaty (28)
  3. Pedram Razavi (25)
  4. Clifford Hudis (24)
  5. Sujata Patil (22)
  6. Gary Ulaner (18)

More People

Years
  1. 2025 (21)
  2. 2024 (34)
  3. 2023 (17)
  4. 2022 (24)
  5. 2021 (26)
  6. 2020 (28)

More Years

Publications
  1. Journal of Clinical Oncology (66)
  2. Cancer Research (33)
  3. Annals of Oncology (22)
  4. Clinical Cancer Research (9)
  5. European Journal of Cancer (5)
  6. Oncology Research and Treatment (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (69)
  2. American Association for Cancer Research (46)
  3. Oxford University Press (23)
  4. Elsevier Inc. (16)
  5. Springer (7)
  6. Nature Publishing Group (6)

More Publishers

Results (215)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Neratinib-based combination therapy in her2-mutant lung adenocarcinomas: Findings from two international phase 2 studies
    Meeting Abstract

    Li, B.; Gandhi, L.; Besse, B.; Jhaveri, K.; Mazières, J.; Boni, V.; Shapiro, G.; Waqar, S.; Viteri, S.; Park, H.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
    Journal Article

    Smyth, L. M.; Batist, G.; Meric-Bernstam, F.; Kabos, P.; Spanggaard, I.; Lluch, A.; Jhaveri, K.; Varga, A.; Wong, A.; Schram, A. M.; more...
    npj Breast Cancer (2021)

    Fulltext@MSK | Save
  • Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC)
    Meeting Abstract

    Turner, N.; Jhaveri, K.; Kalinsky, K.; Loibl, S.; Loi, S.; Im, S. A.; Saura, C.; Schmid, P.; Schutzman, J. L.; Stout, T. J.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Targeted safety events from a phase I/Ib study evaluating GDC-0077 alone and in combination with endocrine therapy (ET) ± palbociclib (palbo) in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)
    Meeting Abstract

    Olivera, M.; Jhaveri, K.; Juric, D.; Bedard, P. L.; Cervantes, A.; Gambardella, V.; Hamilton, E.; Italiano, A.; Kalinsky, K.; Krop, I. E.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • A phase Ib trial of fulvestrant + CDK4/6 inhibitor (CDK4/6i) palbociclib + pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib in FGFR-amplified/ ER+/ HER2-negative metastatic breast cancer (MBC)
    Meeting Abstract

    Mayer, I. A.; Haley, B. B.; Abramson, V. G.; Brufsky, A.; Rexer, B.; Stringer-Reasor, E.; Jhaveri, K. L.; Sanders, M.; Ericsson-Gonzalez, P. I.; Ye, F.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with other anticancer agents in patients with HER2-low metastatic breast cancer: A phase 1b, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast08)
    Meeting Abstract

    Jhaveri, K.; Hamilton, E.; Loi, S.; Schmid, P.; Darilay, A.; Gao, C.; Patel, G.; Wrona, M.; Andre, F.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Preliminary correlative analysis of clinical outcomes with PIK3CA mutation (mut) status from a phase I/Ib study of GDC-0077 in patients (pts) with hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)
    Meeting Abstract

    Jhaveri, K.; Juric, D.; Varga, A.; Turner, N.; Schmid, P.; Saura, C.; Oliveira, M.; Krop, I. E.; Kalinsky, K.; Italiano, A.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Latest findings from the breast cancer cohort in SUMMIT - A phase 2 'basket' trial of neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer
    Meeting Abstract

    Jhaveri, K.; Saura, C.; Guerrero-Zotano, A.; Spanggaard, I.; Bidard, F. C.; Goldman, J. W.; Garcia-Sáenz, J. A.; Cervantes, A.; Boni, V.; Crown, J.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • A phase I/Ib study evaluating GDC-0077 + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)
    Meeting Abstract

    Bedard, P. L.; Jhaveri, K.; Cervantes, A.; Gambardella, V.; Hamilton, E.; Italiano, A.; Kalinsky, K.; Krop, I. E.; Oliveira, M.; Saura, C.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd; DS-8201) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2 open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07)
    Meeting Abstract

    Andre, F.; Hamilton, E.; Loi, S.; Schmid, P.; Yu, T.; Lu, S.; Boston, S.; D'Cruz, C.; Herbolsheimer, P.; Jhaveri, K.
    Cancer Research (2021)

    Fulltext@MSK | Save